Rezultati pretraživanja

  1. Osobe Vidi sve

  2. prije 5 sati

    Create watchlist to track major constituents of 100

  3. prije 6 sati

    Get tweets in 1 watchlist for Social Media stocks

  4. prije 11 sati

    2020-01-31 Short sale volume (not short interest) for is 47%. 48% 43% 26% 59%

  5. prije 19 sati

    : Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?:

  6. 2. velj

    Could Guardant Health Be a Millionaire-Maker Stock?

    2 korisnika označavaju da im se sviđa
  7. 31. sij

    5 Stocks to watch during the outbreak:

    1 korisnik označava da mu se sviđa
  8. 30. sij

    asset watch- active in premarket trading -

    They think it's all done with pixie dust....
    But, in truth, all a lawyer can offer you is experience, ideas, and hard work. If that makes sense to you, give us a call -- (901) 756-7878
  9. 29. sij

    2020-01-28 Short sale volume (not short interest) for is 52%. 49% 55% 57% 41%

  10. 28. sij

    et al. Brief but interesting Pharma Letter article on breast cancer

  11. 23. sij

    CS out with nice slide on earnings dates

    3 proslijeđena tweeta 17 korisnika označava da im se sviđa
  12. 22. sij

    Oppenheimer, “ abandoning Epanova May Weaken Vascepa commercial outlook” Yes!Pepsi agrees to stop making soda CocaCola will immediately file bankruptcy? This may be the dumbest analyst on planet Earth.

    6 replies 2 proslijeđena tweeta 60 korisnika označava da im se sviđa
  13. 21. sij

    AstraZeneca plans to spend $535M-plus to expand its R&D network and manufacturing ops in France

    7 proslijeđenih tweetova 16 korisnika označava da im se sviđa
  14. 21. sij

    7 expected blockbuster drug launches in 2020: - Trastuzumab deruxtecan - Palforzia - Ozanimod - Inclisiran - Roxadustat - Sacituzumab Govitecan - Filgotinib

    21 proslijeđeni tweet 55 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  15. 19. sij

    Good summary of the battle between bispecific antibodies and CARs from Article:

    1 reply 6 proslijeđenih tweetova 24 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  16. 17. sij

    More on Epanova & Capre study failures. Note: STRENGTH study involved 13,000 patients at 675 sites in 22 countries that started in 2014. Decision to terminate with 7 months left to go after DMC reviewed unblinded data. in catbird seat.

    5 proslijeđenih tweetova 37 korisnika označava da im se sviđa
  17. 13. sij

    fish oil drug fails, leaving as last drug standing via

    10 replies 16 proslijeđenih tweetova 56 korisnika označava da im se sviđa
  18. 13. sij

    Is the failure of the STRENGTH trial positive or negative for Vascepa? I say there are legit arguments both ways.

    5 proslijeđenih tweetova 25 korisnika označava da im se sviđa
  19. 13. sij

    Wonder which would have been a better outcome for in terms of more physicians becoming convinced of benefit? A complete failure like this or a marginal benefit considering the differences between compounds

    to discontinue Epanova CVOT STRENGTH due to its low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia (MDL) who are at increased risk of cardiovascular (CV) disease following the recommendation from IDMC
    8 replies 3 proslijeđena tweeta 15 korisnika označava da im se sviđa
  20. 13. sij

    to discontinue Epanova CVOT Trial following the recommendation from IDMC. This is pretty good news all we need is a settlement from trial

    1 reply 5 proslijeđenih tweetova 27 korisnika označava da im se sviđa
  21. 13. sij

    to discontinue Epanova CVOT STRENGTH due to its low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia (MDL) who are at increased risk of cardiovascular (CV) disease following the recommendation from IDMC

    5 replies 27 proslijeđenih tweetova 42 korisnika označavaju da im se sviđa

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.